Cutaneous Adnexal Carcinoma with Apocrine Differentiation: A Challenging Diagnosis and Personalized Treatment with mTOR Inhibitor in a Very Rare Disease

Bibliographic Details
Title: Cutaneous Adnexal Carcinoma with Apocrine Differentiation: A Challenging Diagnosis and Personalized Treatment with mTOR Inhibitor in a Very Rare Disease
Authors: Michela Libertini, Ester Oneda, Brunella Di Biasi, Giordano Savelli, Alberto Zaniboni
Source: Case Reports in Oncology, Vol 13, Iss 3, Pp 1091-1096 (2020)
Publisher Information: Karger Publishers, 2020.
Publication Year: 2020
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: cutaneous adnexal carcinoma, next-generation sequencing test, pi3kca mutation, everolimus, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: Cutaneous adnexal carcinoma with apocrine differentiation is a rare neoplasm arising from cutaneous adnexa, especially of the head and neck and trunk region. Because of its rarity, the diagnosis is challenging and often impossible to distinguish from metastatic cutaneous adenocarcinoma of the breast. The standard of care remains surgery for resectable disease. To date, univocal guidelines for metastatic disease are lacking, particularly regarding systemic therapy. We report a clinical case of a patient diagnosed with cutaneous adnexal adenocarcinoma with apocrine differentiation of the left axilla with lymph node and bone metastasis. We started with carboplatin and paclitaxel chemotherapy regimen, with good response. After progression, we performed a next-generation sequencing analysis (by the Foundation One CDx test) to identify genomic alteration in cancer-related genes. We found PIK3CA and KRAS mutations. Due to this result, the patient started a second-line treatment with a personalized therapy including an mTOR inhibitor, everolimus, and, to date, he is still under treatment. To our knowledge, this is the first case of a patient responding both to chemotherapy and to a personalized treatment with an mTOR inhibitor. It is important to support the value of genomic screening in this rare neoplasm.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1662-6575
Relation: https://www.karger.com/Article/FullText/510097; https://doaj.org/toc/1662-6575
DOI: 10.1159/000510097
Access URL: https://doaj.org/article/12248cb22a59429f8642d261440caf6c
Accession Number: edsdoj.12248cb22a59429f8642d261440caf6c
Database: Directory of Open Access Journals
More Details
ISSN:16626575
DOI:10.1159/000510097
Published in:Case Reports in Oncology
Language:English